Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(Adrenal mass)
12,448 results
  • Primary aldosteronism with nonlocalizing imaging. [Journal Article]
  • SSurgery 2018 Nov 06
  • Wachtel H, Bhandari S, … Fraker DL
  • CONCLUSIONS: Primary aldosteronism patients with nonlocalizing imaging but lateralizing adrenal vein sampling benefit from adrenalectomy. Regardless of imaging findings, adrenal vein sampling is indicated to determine whether patients may be surgically curable.
  • Giant nonfunctioning adrenal tumors: two case reports and review of the literature. [Journal Article]
  • JMJ Med Case Rep 2018 Nov 10; 12(1):335
  • George C, Ioannis P, … Panagiotis S
  • CONCLUSIONS: Approximately 60% of patients with adrenocortical carcinoma present with symptoms and signs of hormonal secretion. Our cases' adrenocortical carcinomas were not functional. Hormone secretion is not a discriminating feature between benign and malignant adrenocortical masses. The silent clinical nature of nonfunctioning adrenocortical carcinoma results in late diagnosis, while the majority of patients present with locally advanced and/or metastatic disease. Adrenocortical carcinoma is a rare endocrine tumor with a poor prognosis that can be diagnostically challenging and demands high clinical suspicion. The work-up for adrenal masses must include determination of whether the mass is functioning or nonfunctioning and whether it is benign or malignant.
  • Impact of Tumor Burden on Quantitative [68Ga] DOTATOC Biodistribution. [Journal Article]
  • MIMol Imaging Biol 2018 Nov 07
  • Werner RA, Hänscheid H, … Rowe SP
  • CONCLUSIONS: There is no significant impact on normal organ biodistribution with increasing tumor burden on [68Ga] DOTATOC PET/CT. Potential implications include increased normal organ dose with [177Lu-DOTA]0-D-Phe1-Tyr3-Octreotide and decreased absolute lesion detection with [68Ga] DOTATOC in high NET burden.
New Search Next